Rezolute reports RZ358 resolves hypoglycemia in tumor-mediated hyperinsulinism patient

Rezolute, Inc.

RZ358 administered on compassionate-use basis to patient with refractory hypoglycemia due to metastatic insulin-secreting cervical cancer.
Treatment started September 2023; resulted in resolution of hypoglycemia and enabled hospital discharge to resume cancer therapy.
Prior metastatic insulinoma patient has remained on RZ358 for nearly a year; case published in NEJM (389;8).
Company sees RZ358 as potential universal treatment for hyperinsulinism; evaluating next steps in additional indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.